Jason Gerberry, an analyst from Bank of America Securities, reiterated the Sell rating on United Therapeutics (UTHR – Research Report). The associated price target is $328.00.
Jason Gerberry has given his Sell rating due to a combination of factors impacting United Therapeutics. The company reported fourth-quarter revenues that met expectations, but its key product, Tyvaso, fell short of consensus estimates by 7%. This shortfall is concerning as Tyvaso has been a significant revenue driver, and the lack of forward revenue guidance adds uncertainty to future performance. Additionally, the absence of new share buyback announcements may have contributed to negative investor sentiment.
Gerberry also highlights competitive pressures facing Tyvaso, particularly from Liquidia’s upcoming Yutrepia launch, which is expected to slow Tyvaso’s growth. Furthermore, there is limited confidence in the company’s pipeline products, with no substantial updates provided. The competitive landscape and potential market share erosion due to new entrants are significant headwinds for United Therapeutics, justifying the Sell rating.
UTHR’s price has also changed slightly for the past six months – from $346.670 to $318.890, which is a -8.01% drop .